OBJECTIVES:: Management of hemophilia A includes replacement of factor VIII (FVIII) by intravenous infusion. The recent introduction of an extended half-life (EHL) FVIII product has enabled comparison of health care expenditure and volumes of factor dispensed for hemophilia A patients switching from a standard half-life (SHL) to EHL FVIII product. METHODS:: The Truven Health Marketscan^® Databases (Jan 2010- Jul 2016) were used to identify medication prescription claims and health care expenditure for patients with claims data for at least 3 months and up to one year before and after switching from an SHL to an EHL product. Total healthcare expenditure included FVIII replacement and hemophilia-related in-patient and out-patient expenditure. Data were analyzed 12 months prior to and after switch in FVIII product. RESULTS::